Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 26;58(2):2101483.
doi: 10.1183/13993003.01483-2021. Print 2021 Aug.

Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry

Karen M Olsson  1   2 , Marius M Hoeper  3   2 , Christine Pausch  4 , Ekkehard Grünig  5 , Doerte Huscher  6 , David Pittrow  4   7 , Stephan Rosenkranz  8 , Henning Gall  2   9
Affiliations
Free article

Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry

Karen M Olsson et al. Eur Respir J. .
Free article
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: K.M. Olsson has received fees for lectures and/or consultations from Actelion, Bayer, Janssen, MSD, United Therapeutics, GSK and Pfizer. Conflict of interest: M.M. Hoeper has received fees for lectures and/or consultations from Acceleron, Actelion, Bayer, GSK, Janssen, MSD and Pfizer. Conflict of interest: C. Pausch has no disclosures. Conflict of interest: E. Grünig received fees for lectures and/or consultations from Actelion, Bayer, GSK, Janssen, MSD, United Therapeutics and Pfizer. Conflict of interest: D. Huscher has received fees for lectures and consultations from Actelion. Conflict of interest: D. Pittrow has received fees for consultations from Actelion, Biogen, Amgen, Aspen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Viatris, Takeda and Sanofi. Conflict of interest: S. Rosenkranz has received fees for lectures and/or consultations from Abbott, Acceleron, Actelion, Bayer, BMS, Gilead, GSK, Janssen, Pfizer, MSD, Novartis, United Therapeutics and Vifor. Conflict of interest: H. Gall reports personal fees for lectures and/or consultations from Actelion, AstraZeneca, Bayer, BMS, Gilead, GSK, Janssen-Cilag, Lilly, MSD, Novartis, OMT, Pfizer, and United Therapeutics.

Comment in

Publication types

LinkOut - more resources